(19)
(11) EP 1 089 727 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
08.03.2006 Bulletin 2006/10

(45) Mention of the grant of the patent:
07.12.2005 Bulletin 2005/49

(21) Application number: 99931721.7

(22) Date of filing: 17.06.1999
(51) International Patent Classification (IPC): 
A61K 31/255(1985.01)
A61P 35/00(2000.01)
 A61K 9/127(1990.01)
(86) International application number:
PCT/SE1999/001093
(87) International publication number:
WO 1999/065481 (23.12.1999 Gazette 1999/51)

(54)

LIPOSOMAL FORMULATIONS OF BUSULPHAN

LIPOSOMFORMULATIONEN MIT BUSULPHAN

PREPARATIONS A BASE DE BUSULPHAN ENCAPSULEES DANS DES LIPOSOMES

(84) Designated Contracting States:
AT BE DE DK ES FI FR GB GR IE IT LU NL PT SE

(30) Priority: 18.06.1998 SE 9802197
18.06.1998 US 89759 P

(43) Date of publication of application:
11.04.2001 Bulletin 2001/15

(73) Proprietors:
  • Hassan, Moustapha, Dr.
    141 44 Huddinge (SE)
  • Hassan, Zuzana
    141 44 Huddinge (SE)

(72) Inventor:
  • HASSAN, Moustapha
    S-129 36 Hägersten (SE)

(74) Representative: Nyberg, Bengt et al
DR. LUDWIG BRANN PATENTBYRA AB, P.O. Box 17192
104 62 Stockholm
104 62 Stockholm (SE)


(56) References cited: : 
EP-A1- 0 546 951
WO-A1-92/22298
 WO-A1-88/06442
WO-A1-95/08991
   
     
    Remarks:
    The file contains technical information submitted after the application was filed and not included in this specification
     
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).